Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

QED Therapeutics, a BridgeBio company · 2019
ClinicalTrials.gov · Datasets · License: Public Domain · 2019
Open Source ↗
cholangiocarcinoma
advanced cholangiocarcinoma, fgfr2 gene mutation, cholangiocarcinoma, unresectable cholangiocarcinoma, metastatic cholangiocarcinoma, fibroblast growth factor receptor inhibitor, fgfr2, fgfr2 gene fusions/translocations, bgj398, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 900490
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.